By
From the * Institute for Genetics and the Institute for Anatomy I, University of Cologne, D-50931
Cologne, Germany; the § Institute for Experimental Immunology, University of Zürich, CH-8093
Zürich, Switzerland; the
Department of Molecular Immunology, Research Institute for Microbial
Diseases, and the ¶ Department of Medicine III, Medical School, Osaka University, Osaka 565, Japan; and the ** Department of Molecular Cell Biology, Medical Research Institute, Tokyo Medical
and Dental University, Tokyo 101, Japan
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The pleiotrophic but overlapping functions of the cytokine family that includes interleukin (IL)-6, IL-11, leukemia inhibitory factor, oncostatin M, ciliary neurotrophic factor, and cardiotrophin 1 are mediated by the cytokine receptor subunit gp130 as the common signal transducer. Although mice lacking individual members of this family display only mild phenotypes, animals lacking gp130 are not viable. To assess the collective role of this cytokine family, we inducibly inactivated gp130 via Cre-loxP-mediated recombination in vivo. Such conditional mutant mice exhibited neurological, cardiac, hematopoietic, immunological, hepatic, and pulmonary defects, demonstrating the widespread importance of gp130-dependent cytokines.
Key words: gene targeting; conditional gene targeting; Cre/loxP technology; gp130-dependent cytokines; gp130 ![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The cytokine network contains various cytokine families whose members share a common subunit in their
receptor complexes (1). One family of cytokines, comprising IL-6, IL-11, leukemia inhibitory factor (LIF),1 oncostatin M (OSM), ciliary neurotrophic factor (CNTF), and
cardiotrophin 1 (CT-1), share the common signal transducer gp130 in their receptors. Individual components of
these cytokine receptor complexes are IL-6R, IL-11R
,
CNTFR
, CT-1R
, LIFR, and OSMR. Signal transduction after ligand binding is elicited by homodimerization of
gp130 in the case of IL-6 and IL-11, by heterodimerization
of gp130 and LIFR in the case of LIF, CNTF, and CT-1,
or by heterodimerization of gp130 and OSMR in the case
of OSM (2, 3). Thereby, the Janus kinase/signal transducer
and activator of transcription (JAK/STAT) pathway (JAK1/
JAK2/TYK2 and STAT1/STAT3/STAT5B) and the RAS/
mitogen-activated protein kinase (RAS-MAPK) pathway
are activated (2).
Mice lacking individual components of this cytokine family or their receptors (IL-6, LIF, CNTF, or IL-11R) displayed milder phenotypes than expected. This is most likely
due to the redundancy of gp130-dependent cytokines (4).
The only phenotype exhibited by mice lacking IL-11R
is
female sterility (7, 8). IL-6-deficient animals exhibit defects
in hematopoiesis (9), antigen-specific antibody production
(except IgM; 4, 10), neutrophilia after infection (11, 12),
TH1 development (12, 13), chemokine induction and leukocyte recruitment (14), acute phase protein (APP) synthesis (4, 15), hepatocyte regeneration (16), fever response (17), neuroglial activation (18), and bone maintenance (19) and display an increased susceptibility to infections with viral, bacterial, fungal, and protozoan pathogens (4, 11). LIF-deficient animals exhibit female sterility due to defective
blastocyst implantation, postnatal growth retardation, and
defects in hematopoiesis and thymocyte proliferation (5, 20).
Not surprisingly, when receptor components used by
several members of the gp130 family are inactivated, the
consequences are more severe. Thus, mutant animals lacking LIFR, a shared component of the receptor complexes
for LIF, CNTF, and CT-1, are not viable and die perinatally, exhibiting placental, skeletal, neural, and metabolic
defects as well as a loss of motor neurons (21, 22). Although
CNTF-deficient mice are only marginally affected by a gradual loss of motor neurons, animals lacking CNTFR
die postnatally (6, 23), suggesting that the CNTFR
has
more than one ligand. Animals deficient for the common
signal transducer gp130 die after day 12.5 postconception
or postnatally, depending on the genetic background (24,
25). These embryos exhibit growth retardation, decreased
hematopoiesis in the fetal liver, and reduced numbers of
primordial germ cells. In addition, they also show a disrupted placental architecture, a hypoplastic ventricular myocardium, and an increased number of osteoclasts (24, 25).
Due to the redundancy of gp130-activating cytokines on one hand and premature lethality of animals lacking shared receptor components on the other, it has so far been impossible to assess the collective physiological role of gp130-dependent cytokines in the adult animal. To answer this question, we inactivated the common signal transducer gp130 inducibly by conditional gene targeting after postnatal lethality had been bypassed (26).
![]() |
Materials and Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Mice
C57BL/6 mice were obtained from Charles River GmbH (Sulzfeld, Germany), and IL-6-deficient mice were provided by H. Mossmann (MPI für Immunologie, Freiburg, Germany). All animals were kept under standard conditions and maintained on acidified water.
Flow Cytometry
Staining was done with fluorochrome (FITC, PE, or CyChrome) or biotin-conjugated mAbs for flow cytometric analysis on a FACScan® (Becton Dickinson, Mountain View, CA). Biotin-conjugated mAb was detected using streptavidin-PE (Southern Biotechnology Associates, Inc., Birmingham, AL). mAb specific for gp130 (RX187) was a gift from K.-I. Akamatsu (Chugai Pharmaceutical Co. Ltd., Tokyo, Japan). mAbs were purchased from PharMingen (San Diego, CA) or Serotec Ltd. (Oxford, UK).
Hematologic Analysis
Blood was taken from mouse tail vein, diluted with PBS, and leukocyte, erythrocyte, and thrombocyte counts were determined by cell counter (model STKS; Coulter Corp., Hialeah, FL). GM-CFU were measured using methylcellulose medium supplemented with recombinant cytokines (Methocult GF M3434; CellSystems, Biotechnologie Vertrieb GmbH, Remagen, Germany) according to the manufacturer's instructions.
Soluble gp130 ELISA
The concentration of soluble gp130 (sgp130) in the blood was determined using a sandwiched ELISA. Plates were coated with anti-gp130 mAb (RX435) to capture sgp130 from the mouse serum. The presence of bound sgp130 was detected with biotinylated anti-gp130 antibody (RX187 [27]) followed by streptavidin-conjugated alkaline phosphatase (Boehringer Mannheim, Mannheim, Germany). Recombinant sgp130 was used as a standard.
Measurement of Acute Phase Response after LPS Injection
Mice were injected intraperitoneally with 1 mg LPS purified from Escherichia coli (Sigma, Deisenhofen, Germany) per kg body wt. Hematic glucose was measured using a Glucometer 3 (Bayer Diagnostic GmbH, München, Germany). The concentration of serum amyloid P (SAP) and C3 in the serum was measured by ELISA using sheep anti-mouse SAP antiserum (Calbiochem Novabiochem GmbH, Bad Soden, Germany), rabbit anti-mouse SAP antiserum (Calbiochem Novabiochem GmbH), alkaline phosphatase-conjugated goat anti-rabbit IgG antiserum (Promega Deutschland GmbH, Mannheim, Germany), goat anti-mouse C3 antiserum (Organon Teknika-Cappel, Durham, NC), and peroxidase-conjugated goat anti-mouse C3 antiserum with a SAP/C3 standard as a reference (Calbiochem Novabiochem GmbH).
Serum Antibody Levels
The concentrations of the different Ig isotypes in the serum were determined by ELISA as described previously (28).
Fixation Procedure
After anesthesia, the lung was perfusion-fixed with 4% paraformaldehyde for 20 min at 15 cm H2O using an intratracheal catheter. Subsequently, mice were transcardially perfused using the same fixative at a perfusion pressure of 60 cm H2O for the same time. Organs were removed and fixed for an additional 4 h in the same fixative.
Light and Electron Microscopy
4% paraformaldehyde perfusion-fixed mouse tissue was postfixed with 2% osmium tetroxide in 0.1 M PBS for 2 h at 4°C. After a thorough wash in 0.1 M phosphate buffer for 10 min three times, the slices were dehydrated in a graded ethanol series and infiltrated with and embedded in araldite. Sections of plastic- embedded specimens were cut with a glass or diamond knife on a Reichert ultramicrotome.
Morphometric Study
For quantification of the ventricular wall thickness, a 2-mm slice perpendicular to the heart axis at the upper half of the ventricular region was cut out, divided in four pieces, and measured in five randomly selected parts of both ventricles at two planes. The myocyte width was measured perpendicular to the long axis of the myocyte slice on 60 randomly selected myocytes of each ventricle using Optimas 6.0. Quantification of the binucleated hepatocytes was performed on methylene blue-stained semithin sections of three specimens from different parts of the liver. 100 hepatocytes of 10 randomly selected areas were counted.
Infection Experiments
Vaccinia.
Mice were infected intravenously with 2 × 106 PFU vaccinia-WR. Viral titers in the lungs were determined at day 5 after infection by plaquing 10-fold dilutions of tissue homogenates on monolayers of BSC40 cells, followed by crystal violet staining after 48 h.Vesicular Stomatitis Virus.
Mice were infected intravenously with 2 × 106 PFU vesicular stomatitis virus, strain Indiana (VSV-IND). Mice were bled on days 4, 8, 12, and 20 after infection, and VSV-neutralizing Ig and IgG antibodies were determined as described (29). The titer was determined by twofold dilution steps of 1:40 prediluted sera, and reduction of IgM was achieved by treating the sera with 0.1 M 2-ME. Titer is defined as the dilution that reduced the number of plaques to half of the control.Listeria.
Mice were infected intravenously with 3 × 103 CFU Listeria monocytogenes. The number of viable bacteria recovered from liver and spleen was determined 5 d after infection by plating 10-fold serial dilutions of organ homogenates on brain-heart infusion agar plates. ![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
A targeting vector was constructed in
which the exon encoding the transmembrane region of
gp130 was flanked with two loxP sites (Fig. 1 a). Homologous recombinant E14 embryonic stem cell colonies were
generated (Fig. 1 b) which had cointegrated the upstream
loxP site (allele: gp130NEO3loxP) (Fig. 1 c). After transient transfection with the Cre-encoding plasmid pICCre, clones were
identified which had deleted neor but not the transmembrane
exon (Fig. 1 d [30]). The resulting allele (gp130flox) can be
inactivated by Cre-loxP-mediated recombination (thereby generating gp130) through removal of the transmembrane
exon and a resulting frame shift. Embryonic stem cells were
injected into C57BL/6 blastocysts. Resulting chimeric
mice were crossed with C57BL/6 animals to establish mice
carrying the gp130flox mutation in the germ line (Fig. 1 e).
As mice homozygous for the gp130flox allele were phenotypically indistinguishable from wild-type animals, the introduction of loxP sites apparently did not affect gp130 expression significantly. To inactivate the loxP-flanked allele in the germ line, gp130flox/flox animals were crossed to Bal1
cre-transgenic mice (31).
|
To allow for inducible
inactivation of gp130, gp130flox/flox animals were crossed to
mice expressing Cre-recombinase under control of the
IFN-responsive Mx1 promoter (Mx-cre [32]). 1-3 d after birth, mice were injected with 5 × 106 U IFN-2/
1 to
induce Cre-mediated recombination (33). 3-4 wk later,
mice were genotyped and tested for the efficiency of Cre-mediated deletion by Southern or FACS® analysis using
anti-gp130 antibody (RX187 [27]). Cre-mediated deletion
of the loxP-flanked allele was close to completion in hematopoietic cells and in hepatocytes, whereas the extent of deletion varied in other organs between 20 and 70% (Fig. 2
a). Possible side effects of IFN-
treatment do not pose a
problem for our analysis of the resulting phenotype, as the
conditional mutants were compared with control animals
that likewise received a postnatal IFN-
injection (34).
|
As expected from
the removal of the transmembrane region, in the blood of
animals carrying a gp130 allele, the concentration of
sgp130 was 20-fold increased compared with gp130+/+ or
gp130flox/flox controls (Fig. 2 b). In inter-crosses between
heterozygous gp130
mice, no viable gp130
/
animals were
obtained. gp130
/
embryos could be found up to day 18.5 after conception but were severely reduced in size compared with their wild-type or heterozygous littermates (not
shown). As measured by FACS® on T cells, gp130 surface
expression was only marginally reduced in gp130
/flox compared with gp130flox/flox mice, whereas cells were gp130
after Cre-mediated recombination in Mx-cre;gp130flox/flox
animals (Fig. 2 c).
Accordingly, Mx-cre;gp130flox/flox mice treated with
IFN-2/
1 as newborns are hereafter referred to as conditional gp130-mutants. These animals exhibited a diverse
phenotype, were weight-reduced, and had a reduced life
span, with 50% of the animals dying before the age of 5 mo
(not shown).
gp130-dependent cytokines have been shown to play an important role in the generation and maintenance of motor neurons (6, 21, 23, 35). Interestingly, in peripheral somatic nerves innervating skeletal leg muscle (musculus gastroceminus), conditional gp130-mutant mice exhibited a degeneration of the myelin sheath (Fig. 3, A-D). The defects on the myelin sheath ranged from disappearance of the laminar structure (Fig. 3 B) to complete loss of myelin (Fig. 3, C and D) and axon lysis (Fig. 3 D). In myocardium as well as in the gut, Schwann cell covering of some small and thick axon bundles was also incomplete in the conditional mutants (Fig. 3, F and G). However, in contrast to the axon terminals, most cell bodies showed an unaltered glia covering (Fig. 3 H). This result shows that gp130-dependent cytokines in adult animals not only influence the survival of motor neurons, as described in mice deficient for CNTF or CNTF/LIF, but also affect Schwann cell covering in myelinated and unmyelinated peripheral nerves.
|
Although the efficiency of Cre-mediated recombination in the heart was low (20-30%; see also Fig. 2 a), distinct morphological alterations were apparent. In the cardiac ventricles of conditional mutant animals, a subpopulation of cardiomyocytes exhibiting a reduction in diameter was detectable. In the left ventricle, for example, 16% of the myocytes from conditional gp130-mutant animals showed a diameter <10 µm, compared with only 2.8% in controls. In addition, conditional gp130-mutants exhibited a thinning of the left (from 792 ± 149 to 619 ± 101 µm) and right (from 344 ± 56 to 248 ± 48 µm) ventricular wall of the heart, and in some cases right ventricular dilation (not shown). As a cardiac defect was also detected in the conventional gp130-deficient embryos (24), this result shows that gp130-dependent cytokines affect cardiomyocyte proliferation or maintenance beyond embryonic development.
Defects in Hematopoiesis in the Absence of gp130-mediated Signals.An influence of gp130-dependent cytokines on hematopoiesis is well established. It was also apparent in mice deficient for IL-6 or LIF, although numbers of circulating white and red blood cells and thrombocytes were still normal (9, 20). In contrast, conditional gp130-mutant mice displayed a reduction in thrombocyte count in the peripheral blood together with an increased number of circulating leukocytes, which is unexplained at the moment. Red blood cell counts were normal (Fig. 4 a). To further assess the role of gp130 in hematopoiesis, we abrogated hematopoiesis by 5-fluoro-5'-deoxyuridine (5-FU) treatment, which kills cycling cells (Fig. 4 b), and determined the ability of the mutant mice to recover. Although leukocytes were generated efficiently in the conditional gp130-mutant animals, resynthesis of erythrocytes and thrombocytes was impaired. A defect in thrombocyte synthesis in the conditional gp130-mutant animals was also apparent after induction of thrombocytopenia by administration of antithrombocyte antiserum, which could not be compensated for by the mutant animals (Fig. 4 c).
|
The number of hematopoietic precursors (CFU-S, GM-CFU) was reduced by 40% in the bone marrow of conditional mutants, whereas in the spleen a twofold increased number of GM-CFU could be detected (not shown). However, the reduction in hematopoietic precursors was more dramatic in gp130-deficient embryos (24).
Accordingly, gp130-dependent cytokines seem to be critically important for establishing the hematopoietic compartment during embryogenesis or after hematopoietic ablation. Under steady state conditions, they continue to play a major role in thrombopoiesis.
IL-6 Is the Principal Member of gp130-dependent Cytokines in the Immune System.In accordance with what is seen in IL-6-deficient mice (4), T cell content in conditional gp130-mutant animals was reduced by 30%, whereas B cell development was not affected. Although IL-6 has been considered to be essential for the terminal differentiation of B cells into Ig-secreting plasma cells (36), mice lacking IL-6 surprisingly displayed normal total serum antibody levels (4). Likewise, in conditional gp130-mutants, no general defect in antibody production could be detected and antibody levels were not reduced compared with controls (Fig. 5). However, the mutants exhibited increased levels of IgG1 and IgE in the blood, indicative for increased IL-4 production, as demonstrated previously in the IL-2-deficient mouse mutant (37).
|
To directly compare the ability of IL-6-deficient and
conditional gp130-mutant mice to control infections with
viral and bacterial pathogens, we infected animals with
VSV, vaccinia virus, and L. monocytogenes. During VSV infection, production of virus-neutralizing IgG was reduced
by three- to fourfold in conditional gp130-mutant animals,
as in IL-6-deficient mice (Fig. 6 a), whereas no significant difference in neutralizing IgM level was detected (Fig. 6 b). Infection with the cytopathic vaccinia virus is controlled by the soluble mediators IFN- and TNF-
, rather than cytotoxic T cells (38). 5 d after infection with vaccinia virus, viral titers in the lung were increased by a factor of 10-
30 in conditional gp130-mutant and IL-6-deficient mice
compared with gp130flox/flox controls (Fig. 6 c). Infections
with L. monocytogenes are controlled by neutrophilic granulocytes and macrophages and cleared by a T cell-dependent
mechanism (41). Also in this case, the pathogen titer was
increased 10-20-fold in spleen (Fig. 6 d) of conditional gp130-deficient animals 5 d after infection, again as observed in IL-6-deficient mice.
|
In summary, the immune system of gp130-deficient animals does not seem to be more severely affected than it is in IL-6-deficient animals. Thus, our data suggest that IL-6 is the principal member of the gp130-dependent cytokine family with regard to immune function.
Morphologic Abnormalities in the gp130-mutant Liver Are Accompanied by a Decreased Ability to Synthesize APP.gp130-dependent cytokines have been reported to play a major
role in liver regeneration and APP synthesis (4, 15, 16, 42).
gp130-mutant livers exhibited a decreased content of binucleated hepatocytes (12.2% compared with 21.4% in controls). Further signs of liver abnormalities in the mutant animals (Fig. 7) were an increased number of Kupffer cells, a
scarce content of rough and smooth endoplasmic reticulum, an increase of lipid vacuoles, an increase of laminar
bodies, a widening of the Disse space and intercellular
space between hepatocytes, dense clustering of mitochondria, reduction and morphological alteration of microvilli,
and a shift in glycogen particles from the rosette to the
monoparticulate
form. However, mitochondria and bile
canaliculi were indistinguishable in mutant and wild-type
liver. In older mice, part of the gp130-mutant liver tissue
was replaced by fibrotic tissue (Fig. 7, C and D).
|
These drastic morphological changes were reflected by a severely decreased ability to synthesize APP. 24 h after intraperitoneal injection of LPS, control animals displayed a considerable increase in the concentration of the APP SAP and complement C3 in the blood. Yet, the conditional gp130-mutant animals failed to do so (Fig. 8 a). Monitoring SAP and blood glucose levels revealed that this was not simply due to a delay in APP synthesis in the mutants (Fig. 8 b).
|
Investigation of the lungs revealed the development of emphysema with increasing age in the conditional gp130-mutant animals. At the age of 6 wk, no sign of emphysema formation or elastin degradation was observable (not shown). Although after 5 mo only a scarce alteration of lung morphology could be observed on methylene blue-stained sections of the mutants, there was a distinct reduction of elastic fibers, as demonstrated by orcein staining (Fig. 9, A and B). However, at the age of 12 mo, a distinct emphysema could be observed in the conditional gp130-mutants, which exhibited an enlargement of the acinus and destruction of respiratory tissue associated with fibrosis (Fig. 9, C and D). Thus, the mutant animals displayed a time-dependent reduction of elastic fibers, followed by the development of lung emphysema, a phenotype unprecedented in the available mutant mice lacking individual components of the gp130-cytokine system.
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The progressive degeneration of peripheral nerves starting with Schwann cell degradation (Fig. 3) cannot be explained by an inflammatory process due to increased pathogen susceptibility of gp130-mutant animals, as the tissue surrounding the damaged nerves did not show any morphologic alterations and the defects are uniform in peripheral vegetative nerve systems, in myocardic and enteric systems, and in somatic nerves in skeleton muscle. As no Schwann cell defect has been described to date in conjunction with the motor neuron deficits of CNTF- or LIF/CNTF-deficient mice (6, 35), it is conceivable that an as yet uncloned ligand is the main mediator for gp130 signals on Schwann cells. Alternatively, the observed defect may become apparent only after simultaneous inactivation of several gp130-dependent cytokines, as various family members have been reported to enhance the survival of oligodendrocytes in vitro (43).
gp130 Signals Are Important for Thrombopoiesis.The analysis presented here points to a special importance of gp130-dependent cytokines for the synthesis of thrombocytes, as already under steady state conditions thrombocyte number was reduced in the absence of functional gp130 (Fig. 4). It has been shown previously that IL-6, IL-11, LIF, OSM, IL-3, and thrombopoietin can increase platelet production (44). In addition, IL-6 transgenic mice showed an increase in the number of mature multinuclear megakaryocytes in the bone marrow (45). Nevertheless, neither IL-6-, IL-11R-, nor LIF-deficient mice displayed decreased platelet counts, although IL-6-deficient mice had lower numbers of CFU-MK (9). The redundant function of gp130-dependent cytokines with regard to thrombocyte production is reflected by the fact that inactivation of gp130 produced a more severe phenotype than inactivation of any single ligand.
Redundancy among Different gp130-dependent Cytokines Does Not Play a Major Role in the Immune System.The effects of gp130 deficiency in the immune system do not seem to be more severe than those caused by the absence of IL-6 alone, as judged by T cell numbers, total Ig content in the blood (Fig. 5), antigen-specific antibody production, and susceptibility to infection by viral and bacterial pathogens (Fig. 6). This argues against a major regulatory role of gp130-dependent cytokines in the immune system apart from IL-6, indicating that redundancy among different family members is not widespread in the regulation of immunity. Also, gp130 inactivation was very efficient; in hematopoietic cells, the possibility exists that remaining wild-type cells were selected during immune responses, thereby attenuating the phenotype displayed by the conditional mutants.
gp130 Plays a Major Role in the Acute Phase Response and Lung Physiology.The importance of IL-6 for hepatocytes has only been apparent under stress conditions, e.g, provoked by localized tissue damage or partial hepatectomy (4, 15, 16). In contrast, in the absence of gp130, profound histological changes arose spontaneously in the liver (Fig. 7). Likewise, although APP production after injection of LPS was almost normal in IL-6-deficient mice (4, 15), in gp130-mutant mice no increased synthesis of APP could be detected (Fig. 8). This could reflect a specific role of gp130- dependent cytokines other than IL-6 in the induction of APP synthesis or a general synthetic deficiency of gp130-deficient hepatocytes, which exhibit drastic morphological alterations including an underdeveloped endoplasmic reticulum.
Conditional gp130-mutant animals developed emphysema with increasing age, starting with elastic fiber degradation (Fig. 9). If neutrophil elastase activity during infections cannot be efficiently held in check by antiproteases,
which are a major component of the APP, elastin digestion
and finally emphysema development results (46). Accordingly, humans suffering from congenital 1-antitrypsin deficiency suffer from emphysema with increasing age (47).
In this regard, it is interesting to note that apart from hepatocytes, lung epithelial cells are also a source of antiproteases. Here synthesis can be stimulated by OSM, but not
by other gp130-dependent cytokines (47, 48). This predicts
that OSM-deficient or OSM/IL-6 double mutant animals
may likewise suffer from emphysema development.
Taken together, we were able to assess the function of gp130 by ablating the common signal transducer gp130 in mice after birth. The observed demyelination of peripheral nerves, thrombocytopenia, the disrupted liver architecture in combination with an impaired acute phase response, and the formation of emphysema in the lung did not occur in animals lacking individual members of the gp130-dependent cytokine family generated to date. Thus, either these effects become apparent only when several gp130-dependent cytokines have been inactivated simultaneously or they are due to uncharacterized family members. The diverse phenotype of conditional gp130-mutant animals demonstrates the widespread importance of gp130-dependent cytokines, and points to their potential therapeutic use in conditions such as emphysema formation, thrombocytopenia, and nerve degeneration.
![]() |
Footnotes |
---|
Address correspondence to Werner Müller, Institute for Genetics, Weyertal 121, D-50931 Cologne, Germany. Fax: 49-221-470-5185; E-mail: w.mueller{at}uni-koeln.de
Received for publication 13 August 1998.
U.A.K. Betz's present address is Pharma Research Antiinfectives, Bayer AG, D-42096 Wuppertal, Germany.We thank K.-I. Akamatsu (Chugai Pharmaceutical Co. Ltd., Tokyo, Japan) for anti-gp130 antibody
(RX187), C. Weissmann for recombinant IFN-2/
1, V. Poli for ELISA protocols, M. Kopf and H. Mossmann for IL-6-deficient animals, and R. Zinkernagel and L. Pao for reading the manuscript.
This work was supported by the Bundesministerium für Bildung, Wissenschaft, Forschung und Technologie, Förderkennzeichen 01 KS 9502 (Zentrum für Molekularbiologische Medizin Köln [ZMMK], Cologne).
Abbreviations used in this paper APP, acute phase protein(s); CNTF, ciliary neurotrophic factor; CT-1, cardiotrophin 1; JAK, Janus kinase; LIF, leukemia inhibitory factor; MAPK, mitogen-activated protein kinase; OSM, oncostatin M; s, soluble; SAP, serum amyloid P; STAT, signal transducer and activator of transcription; VSV, vesicular stomatitis virus.
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Kishimoto, T., T. Taga, and S. Akira. 1994. Cytokine signal transduction. Cell. 76: 253-262 [Medline]. |
2. | Taga, T., and T. Kishimoto. 1997. Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 15: 797-819 [Medline]. |
3. |
Ichihara, M.,
T. Hara,
H. Kim,
T. Murate, and
A. Miyajima.
1997.
Oncostatin M and leukemia inhibitory factor do not
use the same functional receptor in mice.
Blood.
90:
165-173
|
4. | Kopf, M., H. Baumann, G. Freer, M. Freudenberg, M. Lamers, T. Kishimoto, R. Zinkernagel, H. Bluethmann, and G. Kohler. 1994. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 368: 339-342 [Medline]. |
5. | Stewart, C.L., P. Kaspar, L.J. Brunet, H. Bhatt, I. Gadi, F. Köntgen, and S.J. Abbondanzo. 1992. Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. Nature. 359: 76-79 [Medline]. |
6. | Masu, Y., E. Wolf, B. Holtmann, M. Sendtner, G. Brem, and H. Thoenen. 1993. Disruption of the CNTF gene results in motor neuron degeneration. Nature. 365: 27-32 [Medline]. |
7. |
Nandurkar, H.H.,
L. Robb,
D. Tarlinton,
L. Barnett,
F. Köntgen, and
C.G. Begley.
1997.
Adult mice with targeted
mutation of the interleukin-11 receptor (IL11R![]() |
8. | Robb, L., R. Li, L. Hartley, H.H. Nandurkar, F. Köntgen, and C.G. Begley. 1998. Infertility in female mice lacking the receptor for interleukin 11 is due to a defective uterine response to implantation. Nat. Med. 4: 303-308 [Medline]. |
9. | Bernad, A., M. Kopf, R. Kulbacki, N. Weich, G. Koehler, and J.C. Gutierrez-Ramos. 1994. Interleukin-6 is required in vivo for the regulation of stem cells and committed progenitors of the hematopoietic system. Immunity. 1: 725-731 [Medline]. |
10. | Ramsay, A.J., A.J. Husband, I.A. Ramshaw, S. Bao, K.I. Matthaei, G. Koehler, and M. Kopf. 1994. The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science. 264: 561-563 [Medline]. |
11. | Dalrymple, S.A., L.A. Lucian, R. Slattery, T. McNeil, D.M. Aud, S. Fuchino, F. Lee, and R. Murray. 1995. Interleukin-6-deficient mice are highly susceptible to Listeria monocytogenes infection: correlation with inefficient neutrophilia. Infect. Immun. 63: 2262-2268 [Abstract]. |
12. | Romani, L., A. Mencacci, E. Cenci, R. Spaccapelo, C. Toniatti, P. Puccetti, F. Bistoni, and V. Poli. 1996. Impaired neutrophil response and CD4+ T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. J. Exp. Med. 183: 1345-1355 [Abstract]. |
13. | Suzuki, Y., S. Rani, O. Liesenfeld, T. Kojima, S. Lim, T.A. Nguyen, S.A. Dalrymple, R. Murray, and J.S. Remington. 1997. Impaired resistance to the development of toxoplasmic encephalitis in interleukin-6-deficient mice. Infect. Immun. 65: 2339-2345 [Abstract]. |
14. | Romano, M., M. Sironi, C. Toniatti, N. Polentarutti, P. Fruscella, P. Ghezzi, R. Faggioni, W. Luini, V. van Hinsbergh, S. Sozzani, et al . 1997. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity. 6: 315-325 [Medline]. |
15. | Fattori, E., M. Cappelletti, P. Costa, C. Sellitto, L. Cantoni, M. Carelli, R. Faggioni, G. Fantuzzi, P. Ghezzi, and V. Poli. 1994. Defective inflammatory response in interleukin 6-deficient mice. J. Exp. Med. 180: 1243-1250 [Abstract]. |
16. |
Cressman, D.E.,
L.E. Greenbaum,
R.A. De Angelis,
G. Ciliberto,
E.E. Furth,
V. Poli, and
R. Taub.
1996.
Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice.
Science.
274:
1379-1383
|
17. |
Chai, Z.,
S. Gatti,
C. Toniatti,
V. Poli, and
T. Bartfai.
1996.
Interleukin (IL)-6 gene expression in the central nervous system is necessary for fever response to lipopolysaccharide or
IL-1![]() |
18. | Klein, M.A., J.C. Moller, L.L. Jones, H. Bluethmann, G.W. Kreutzberg, and G. Raivich. 1997. Impaired neuroglial activation in interleukin-6 deficient mice. Glia. 19: 227-233 [Medline]. |
19. | Poli, V., R. Balena, E. Fattori, A. Markatos, M. Yamamoto, H. Tanaka, G. Ciliberto, G.A. Rodan, and F. Costantini. 1994. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 13: 1189-1196 [Abstract]. |
20. | Escary, J.L., J. Perreau, D. Dumenil, S. Ezine, and P. Brulet. 1993. Leukaemia inhibitory factor is necessary for maintenance of haematopoietic stem cells and thymocyte stimulation. Nature. 363: 361-364 [Medline]. |
21. |
Ware, C.B.,
M.C. Horowitz,
B.R. Renshaw,
J.S. Hunt,
D. Liggitt,
S.A. Koblar,
B.C. Gliniak,
H.J. McKenna,
T. Papayannopoulou,
B. Thoma, et al
.
1995.
Targeted disruption of
the low-affinity leukemia inhibitory factor receptor gene
causes placental, skeletal, neural and metabolic defects and results in perinatal death.
Development.
121:
1283-1299
|
22. | Li, M., M. Sendtner, and A. Smith. 1995. Essential function of LIF receptor in motor neurons. Nature. 378: 724-727 [Medline]. |
23. | De Chiara, T.M., R. Vejsada, W.T. Poueymirou, A. Acheson, C. Suri, J.C. Conover, B. Friedman, J. McClain, L. Pan, N. Stahl, et al . 1995. Mice lacking the CNTF receptor, unlike mice lacking CNTF, exhibit profound motor neuron deficits at birth. Cell. 83: 313-322 [Medline]. |
24. |
Yoshida, K.,
T. Taga,
M. Saito,
S. Suematsu,
A. Kumanogoh,
T. Tanaka,
H. Fujiwara,
M. Hirata,
T. Yamagami,
T. Nakahata, et al
.
1996.
Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders.
Proc.
Natl. Acad. Sci. USA.
93:
407-411
|
25. |
Kawasaki, K.,
Y.H. Gao,
S. Yokose,
Y. Kaji,
T. Nakamura,
T. Suda,
K. Yoshida,
T. Taga,
T. Kishimoto,
H. Kataoka, et al
.
1997.
Osteoclasts are present in gp130-deficient mice.
Endocrinology.
138:
4959-4965
|
26. |
Rajewsky, K.,
H. Gu,
R. Kühn,
U.A. Betz,
W. Müller,
J. Roes, and
F. Schwenk.
1996.
Conditional gene targeting.
J.
Clin. Invest.
98:
600-603
|
27. |
Broudy, V.C.,
N.L. Lin,
N. Fox,
T. Taga,
M. Saito, and
K. Kaushansky.
1996.
Thrombopoietin stimulates colony-forming unit-megakaryocyte proliferation and megakaryocyte
maturation independently of cytokines that signal through
the gp130 receptor subunit.
Blood.
88:
2026-2032
|
28. | Roes, J., and K. Rajewsky. 1993. Immunoglobulin D (IgD)- deficient mice reveal an auxiliary receptor function for IgD in antigen-mediated recruitment of B cells. J. Exp. Med. 177: 45-55 [Abstract]. |
29. | Bachmann, M.F., T.M. Kundig, C.P. Kalberer, H. Hengartner, and R.M. Zinkernagel. 1993. Formalin inactivation of vesicular stomatitis virus impairs T-cell- but not T-help- independent B-cell responses. J. Virol. 67: 3917-3922 [Abstract]. |
30. | Gu, H., Y.R. Zou, and K. Rajewsky. 1993. Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre-loxP-mediated gene targeting. Cell. 73: 1155-1164 [Medline]. |
31. | Betz, U.A., C.A. Vosshenrich, K. Rajewsky, and W. Müller. 1996. Bypass of lethality with mosaic mice generated by Cre-loxP-mediated recombination. Curr. Biol. 6: 1307-1316 [Medline]. |
32. | Kühn, R., F. Schwenk, M. Aguet, and K. Rajewsky. 1995. Inducible gene targeting in mice. Science. 269: 1427-1429 [Medline]. |
33. | Weber, H., D. Valenzuela, G. Lujber, M. Gubler, and C. Weissmann. 1987. Single amino acid changes that render human IFN-alpha 2 biologically active on mouse cells. EMBO J. 6: 591-598 [Abstract]. |
34. |
Lin, Q.,
C. Dong, and
M.D. Cooper.
1998.
Impairment of T
and B cell development by treatment with a type I interferon.
J. Exp. Med.
187:
79-87
|
35. | Sendtner, M., R. Gotz, B. Holtmann, J.L. Escary, Y. Masu, P. Carroll, E. Wolf, G. Brem, P. Brulet, and H. Thoenen. 1996. Cryptic physiological trophic support of motoneurons by LIF revealed by double gene targeting of CNTF and LIF. Curr. Biol. 6: 686-694 [Medline]. |
36. | Muraguchi, A., T. Hirano, B. Tang, T. Matsuda, Y. Horii, K. Nakajima, and T. Kishimoto. 1988. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J. Exp. Med. 167: 332-344 [Abstract]. |
37. | Sadlack, B., R. Kühn, H. Schorle, K. Rajewsky, W. Müller, and I. Horak. 1994. Development and proliferation of lymphocytes in mice deficient for both interleukins-2 and -4. Eur. J. Immunol. 24: 281-284 [Medline]. |
38. |
Spriggs, M.K.,
B.H. Koller,
T. Sato,
P.J. Morrissey,
W.C. Fanslow,
O. Smithies,
R.F. Voice,
M.B. Widmer, and
C.R. Maliszewski.
1992.
Beta 2-microglobulin![]() |
39. | Huang, S., W. Hendriks, A. Althage, S. Hemmi, H. Bluethmann, R. Kamijo, J. Vilcek, R.M. Zinkernagel, and M. Aguet. 1993. Immune response in mice that lack the interferon-gamma receptor. Science. 259: 1742-1745 [Medline]. |
40. | Ramsay, A.J., J. Ruby, and I.A. Ramshaw. 1993. A case for cytokines as effector molecules in the resolution of virus infection. Immunol. Today. 14: 155-157 [Medline]. |
41. | Unanue, E.R.. 1997. Studies in listeriosis show the strong symbiosis between the innate cellular system and the T-cell response. Immunol. Rev. 158: 11-25 [Medline]. |
42. |
Benigni, F.,
G. Fantuzzi,
S. Sacco,
M. Sironi,
P. Pozzi,
C.A. Dinarello,
J.D. Sipe,
V. Poli,
M. Cappelletti,
G. Paonessa, et al
.
1996.
Six different cytokines that share GP130 as a receptor subunit, induce serum amyloid A and potentiate the
induction of interleukin-6 and the activation of the hypothalamus-pituitary-adrenal axis by interleukin-1.
Blood.
87:
1851-1854
|
43. |
Barres, B.A.,
R. Schmid,
M. Sendnter, and
M.C. Raff.
1993.
Multiple extracellular signals are required for long-term oligodendrocyte survival.
Development (Camb.).
118:
283-295
|
44. |
Wallace, P.M.,
J.F. MacMaster,
J.R. Rillema,
J. Peng,
S.A. Burstein, and
M. Shoyab.
1995.
Thrombocytopoietic properties of oncostatin M.
Blood.
86:
1310-1315
|
45. | Suematsu, S., T. Matsuda, K. Aozasa, S. Akira, N. Nakano, S. Ohno, J. Miyazaki, K. Yamamura, T. Hirano, and T. Kishimoto. 1989. IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc. Natl. Acad. Sci. USA. 86: 7547-7551 [Abstract]. |
46. | Travis, J., and G.S. Salvesen. 1983. Human plasma proteinase inhibitors. Annu. Rev. Biochem. 52: 655-709 [Medline]. |
47. |
Perlmutter, D.H., and
J.A. Pierce.
1989.
The alpha 1-antitrypsin gene and emphysema.
Am. J. Physiol.
257:
L147-L162
|
48. | Cichy, J., S. Rose-John, and J. Travis. 1998. Oncostatin M, leukaemia-inhibitory factor and interleukin 6 trigger different effects on alpha1-proteinase inhibitor synthesis in human lung-derived epithelial cells. Biochem. J. 329: 335-339 [Medline]. |
49. | Sallenave, J.M., G.M. Tremblay, J. Gauldie, and C.D. Richards. 1997. Oncostatin M, but not interleukin-6 or leukemia inhibitory factor, stimulates expression of alpha1-proteinase inhibitor in A549 human alveolar epithelial cells. J. Interferon Cytokine Res. 17: 337-346 [Medline]. |